Clinical Oncology NewsAdjuvant Therapy Fails for High-Risk Soft Tissue SarcomaClinical Oncology NewsIn most oncology patients, one can get cyclophosphamide-doxorubicin or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) any…
Smart Strategies for Savings Presented at ASHP MeetingPharmacy Practice NewsThe cost for inpatient rituximab (Rituxan, Genentech) alone decreased from baseline by more than $250,000 in FY10 and by $150,000 in FY11. The driving force behind the savings …
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab …7thSpace Interactive (press release)In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) trea…
The Best Big Biotech for 2013DailyFinanceResults from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership with AbbVie , are expected in 2014. Celgene Celgene provided upbeat product and financial updates. CEO Bob…
The Best Big Biotech for 2013Motley FoolThe company also anticipates phase 3 results for PEG Interferon Beta-1A in the first half of this year. Results from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership wit…
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma of the Thyroid7thSpace Interactive (press release)She promptly underwent surgery with resection of the thyroid tumor, and the diagnosis of THRLBCL was established pathologically. She was successfully treated…
|
Modified Antibodies Trigger Immune Response, Point to Novel Vaccine Design …
Newswise (press release) Newswise — CAMBRIDGE, Mass. (January 7, 2013) – In an approach with the potential to aid therapeutic vaccine development, Whitehead Institute scientists have shown that enzymatically modified antibodies can be used to generate highly targeted, potent … |
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma …7thSpace Interactive (press release)She experienced a relapse 19 months later with involvement of the retroperitoneal lymph nodes, and commenced treatment with rituximab an…
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
PharmiWeb.com (press release) Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
Fort Mills Times Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |